Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 2, 2011British Journal of DermatologyOpen Access

Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies

View Full Paper
Ask AI
Bookmark
Share

Authors

JFJoseph F. FowlerNational Institute of Standards and TechnologyMJMichael JarrattBoston Children's HospitalAMAngela MooreBaylor University Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fowler et al. (2011) studied this question.

synapsesocial.com/papers/6a8165a126f0d7dff79cd837https://doi.org/10.1111/j.1365-2133.2011.10716.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A 1-Year Study of Brimonidine Twice Daily in Glaucoma and Ocular Hypertension1997 · 199 citations
  2. 2Topical Metronidazole Does Not Abate UVB-Induced Erythema2001 · 8 citations
  3. 3Silent α2C-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries2000 · 278 citations
  4. 4The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities2010 · 148 citations
  5. 5Successful Treatment of the Erythema and Flushing of Rosacea Using a Topically Applied Selective α1-Adrenergic Receptor Agonist, Oxymetazoline2007 · 103 citations